Cargando…
Prognostic value of ERBB4 expression in patients with triple negative breast cancer
BACKGROUND: Triple-negative breast cancer (TNBC) is known for aggressive biologic features and poor prognosis. Epidermal growth factor receptor (EGFR) overexpression in TNBC indicates poor prognosis. However, there is no previous study of the relationship between expression of the entire human epide...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4763414/ https://www.ncbi.nlm.nih.gov/pubmed/26907936 http://dx.doi.org/10.1186/s12885-016-2195-3 |
_version_ | 1782417255676510208 |
---|---|
author | Kim, Ji-Yeon Jung, Hae Hyun Do, In-Gu Bae, SooYoun Lee, Se Kyung Kim, Seok Won Lee, Jeong Eon Nam, Seok Jin Ahn, Jin Seok Park, Yeon Hee Im, Young-Hyuck |
author_facet | Kim, Ji-Yeon Jung, Hae Hyun Do, In-Gu Bae, SooYoun Lee, Se Kyung Kim, Seok Won Lee, Jeong Eon Nam, Seok Jin Ahn, Jin Seok Park, Yeon Hee Im, Young-Hyuck |
author_sort | Kim, Ji-Yeon |
collection | PubMed |
description | BACKGROUND: Triple-negative breast cancer (TNBC) is known for aggressive biologic features and poor prognosis. Epidermal growth factor receptor (EGFR) overexpression in TNBC indicates poor prognosis. However, there is no previous study of the relationship between expression of the entire human epidermal growth factor receptor (HER) family genes and patient prognosis in TNBC. Accordingly, we investigated the expression profiles of HER family genes in patients with TNBC to determine the prognostic value and clinical implications of HER family expression. METHODS: We used the nCounter expression assay (NanoString®) to measure the expression of EGFR, erb-B2 receptor tyrosine kinase 2 (ERBB2), ERBB3, ERBB4, and estrogen receptor 1 (ESR1) genes using mRNA extracted from paraffin-embedded tumor tissues from 203 patients diagnosed with TNBC. Our data were validated using a separate cohort of 84 TNBC patients. RESULTS: A total of 203 TNBC patients who received adjuvant chemotherapy after curative surgery from 2000 to 2004 formed the training set. The 84 TNBC patients in the validation consort were selected from breast cancer patients who received curative surgery since 2005 to 2010. Analysis of the expression profiles of the HER family genes in TNBC tissue specimens revealed that increased expression of ERBB4 was associated with poor prognosis according to survival analysis (5-year distant relapse free survival [5Y DRFS], low vs. high expression [cut-off: median]: 90.1 % vs. 80.2 %; p = 0.022). This trend was also observed in the validation set of TNBC patients (5Y DRFS, low vs. high: 69.4 % vs. 44.7 %; p = 0.053). In a multivariate Cox regression model, ERBB4 expression was identified as a indicator of long-term prognosis in patients with TNBC. CONCLUSIONS: The expression profile of ERBB4, a member of the HER family, might serve as a prognostic marker in patients with TNBC. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-016-2195-3) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4763414 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-47634142016-02-24 Prognostic value of ERBB4 expression in patients with triple negative breast cancer Kim, Ji-Yeon Jung, Hae Hyun Do, In-Gu Bae, SooYoun Lee, Se Kyung Kim, Seok Won Lee, Jeong Eon Nam, Seok Jin Ahn, Jin Seok Park, Yeon Hee Im, Young-Hyuck BMC Cancer Research Article BACKGROUND: Triple-negative breast cancer (TNBC) is known for aggressive biologic features and poor prognosis. Epidermal growth factor receptor (EGFR) overexpression in TNBC indicates poor prognosis. However, there is no previous study of the relationship between expression of the entire human epidermal growth factor receptor (HER) family genes and patient prognosis in TNBC. Accordingly, we investigated the expression profiles of HER family genes in patients with TNBC to determine the prognostic value and clinical implications of HER family expression. METHODS: We used the nCounter expression assay (NanoString®) to measure the expression of EGFR, erb-B2 receptor tyrosine kinase 2 (ERBB2), ERBB3, ERBB4, and estrogen receptor 1 (ESR1) genes using mRNA extracted from paraffin-embedded tumor tissues from 203 patients diagnosed with TNBC. Our data were validated using a separate cohort of 84 TNBC patients. RESULTS: A total of 203 TNBC patients who received adjuvant chemotherapy after curative surgery from 2000 to 2004 formed the training set. The 84 TNBC patients in the validation consort were selected from breast cancer patients who received curative surgery since 2005 to 2010. Analysis of the expression profiles of the HER family genes in TNBC tissue specimens revealed that increased expression of ERBB4 was associated with poor prognosis according to survival analysis (5-year distant relapse free survival [5Y DRFS], low vs. high expression [cut-off: median]: 90.1 % vs. 80.2 %; p = 0.022). This trend was also observed in the validation set of TNBC patients (5Y DRFS, low vs. high: 69.4 % vs. 44.7 %; p = 0.053). In a multivariate Cox regression model, ERBB4 expression was identified as a indicator of long-term prognosis in patients with TNBC. CONCLUSIONS: The expression profile of ERBB4, a member of the HER family, might serve as a prognostic marker in patients with TNBC. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-016-2195-3) contains supplementary material, which is available to authorized users. BioMed Central 2016-02-22 /pmc/articles/PMC4763414/ /pubmed/26907936 http://dx.doi.org/10.1186/s12885-016-2195-3 Text en © Kim et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Kim, Ji-Yeon Jung, Hae Hyun Do, In-Gu Bae, SooYoun Lee, Se Kyung Kim, Seok Won Lee, Jeong Eon Nam, Seok Jin Ahn, Jin Seok Park, Yeon Hee Im, Young-Hyuck Prognostic value of ERBB4 expression in patients with triple negative breast cancer |
title | Prognostic value of ERBB4 expression in patients with triple negative breast cancer |
title_full | Prognostic value of ERBB4 expression in patients with triple negative breast cancer |
title_fullStr | Prognostic value of ERBB4 expression in patients with triple negative breast cancer |
title_full_unstemmed | Prognostic value of ERBB4 expression in patients with triple negative breast cancer |
title_short | Prognostic value of ERBB4 expression in patients with triple negative breast cancer |
title_sort | prognostic value of erbb4 expression in patients with triple negative breast cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4763414/ https://www.ncbi.nlm.nih.gov/pubmed/26907936 http://dx.doi.org/10.1186/s12885-016-2195-3 |
work_keys_str_mv | AT kimjiyeon prognosticvalueoferbb4expressioninpatientswithtriplenegativebreastcancer AT junghaehyun prognosticvalueoferbb4expressioninpatientswithtriplenegativebreastcancer AT doingu prognosticvalueoferbb4expressioninpatientswithtriplenegativebreastcancer AT baesooyoun prognosticvalueoferbb4expressioninpatientswithtriplenegativebreastcancer AT leesekyung prognosticvalueoferbb4expressioninpatientswithtriplenegativebreastcancer AT kimseokwon prognosticvalueoferbb4expressioninpatientswithtriplenegativebreastcancer AT leejeongeon prognosticvalueoferbb4expressioninpatientswithtriplenegativebreastcancer AT namseokjin prognosticvalueoferbb4expressioninpatientswithtriplenegativebreastcancer AT ahnjinseok prognosticvalueoferbb4expressioninpatientswithtriplenegativebreastcancer AT parkyeonhee prognosticvalueoferbb4expressioninpatientswithtriplenegativebreastcancer AT imyounghyuck prognosticvalueoferbb4expressioninpatientswithtriplenegativebreastcancer |